CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Country • United States
    Entity • country not supported, please select another country
    English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文

    Trade Quince Therapeuticks Inc - QNCX CFD

    1.5486
    0%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0328
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.024874 %
    Charges from borrowed part ($-0.99)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		-0.024874%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.002651 %
    Charges from borrowed part ($0.11)
    Trade size with leverage ~ $5,000.00
    Money from leverage ~ $4,000.00
    Go to platform
    		0.002651%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 20%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Key Stats
    Prev. Close* 1.5486
    Open* 1.4886
    1-Year Change* -75.76%
    Day's Range* 1.4886 - 1.5586
    52 wk Range 0.54-6.80
    Average Volume (10 days) 5.94M
    Average Volume (3 months) 47.55M
    Market Cap 55.87M
    P/E Ratio -100.00K
    Shares Outstanding 36.28M
    Revenue N/A
    EPS -1.61
    Dividend (Yield %) N/A
    Beta 1.31
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Mar 31, 2023 1.5486 0.0600 4.03% 1.4886 1.5686 1.4886
    Mar 30, 2023 1.5486 0.0500 3.34% 1.4986 1.5686 1.4886
    Mar 29, 2023 1.5386 0.0499 3.35% 1.4887 1.5686 1.4687
    Mar 28, 2023 1.4687 0.0100 0.69% 1.4587 1.5186 1.4487
    Mar 27, 2023 1.4487 0.0200 1.40% 1.4287 1.5486 1.4287
    Mar 24, 2023 1.4587 0.0600 4.29% 1.3987 1.4787 1.3488
    Mar 23, 2023 1.3588 -0.0899 -6.21% 1.4487 1.4687 1.3488
    Mar 22, 2023 1.4187 0.0200 1.43% 1.3987 1.4687 1.3688
    Mar 21, 2023 1.4187 0.0000 0.00% 1.4187 1.5186 1.3388
    Mar 20, 2023 0.8196 0.0004 0.05% 0.8192 0.8360 0.7892
    Mar 17, 2023 0.8188 -0.0171 -2.05% 0.8359 0.8359 0.7848
    Mar 16, 2023 0.8193 -0.0066 -0.80% 0.8259 0.8557 0.7919
    Mar 15, 2023 0.8410 -0.0382 -4.34% 0.8792 0.8792 0.8155
    Mar 14, 2023 0.8716 -0.0339 -3.74% 0.9055 0.9155 0.8691
    Mar 13, 2023 0.8791 -0.0663 -7.01% 0.9454 0.9454 0.8656
    Mar 10, 2023 0.9237 -0.0326 -3.41% 0.9563 0.9752 0.9237
    Mar 9, 2023 0.9743 -0.0247 -2.47% 0.9990 1.0490 0.9643
    Mar 8, 2023 0.9832 0.0080 0.82% 0.9752 0.9950 0.9393
    Mar 7, 2023 0.9591 0.0079 0.83% 0.9512 0.9784 0.9491
    Mar 6, 2023 0.9667 0.0023 0.24% 0.9644 0.9868 0.9433

    Quince Therapeuticks Inc Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 52.015 90.318 78.893 39.168 12.119
    Selling/General/Admin. Expenses, Total 26.012 29.523 17.586 8.954 2.034
    Research & Development 25.178 60.795 61.307 30.214 10.085
    Operating Income -52.015 -90.318 -78.893 -39.168 -12.119
    Interest Income (Expense), Net Non-Operating 1.068 0.62 2.044 2.188 -0.357
    Net Income Before Taxes -51.944 -89.945 -76.849 -36.98 -12.476
    Net Income After Taxes -51.66 -89.945 -76.849 -36.98 -12.476
    Net Income Before Extra. Items -51.66 -89.945 -76.849 -36.98 -12.476
    Total Extraordinary Items
    Net Income -51.66 -89.945 -76.849 -36.98 -12.476
    Income Available to Common Excl. Extra. Items -51.66 -89.945 -76.849 -36.98 -12.476
    Income Available to Common Incl. Extra. Items -51.66 -89.945 -76.849 -36.98 -12.476
    Diluted Net Income -51.66 -89.945 -76.849 -36.98 -12.476
    Diluted Weighted Average Shares 33.4965 29.7185 29.1762 19.0319 26.0133
    Diluted EPS Excluding Extraordinary Items -1.54225 -3.02657 -2.63396 -1.94305 -0.4796
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -1.52624 -3.02657 -2.63396 -1.94305 -0.4796
    Other, Net -0.997 -0.247
    Unusual Expense (Income) 0.825
    Dec 2022 Sep 2022 Jun 2022 Mar 2022 Dec 2021
    Total revenue 0 0 0 0 0
    Total Operating Expense 6.319 7.62 16.258 21.863 23.544
    Selling/General/Admin. Expenses, Total 3.551 4.344 9.059 9.106 8.331
    Research & Development 2.768 2.451 7.199 12.757 15.213
    Operating Income -6.319 -7.62 -16.258 -21.863 -23.544
    Interest Income (Expense), Net Non-Operating 0.536 0.315 0.145 0.072 0.105
    Net Income Before Taxes -5.534 -7.921 -16.848 -21.641 -23.399
    Net Income After Taxes -5.534 -7.921 -16.564 -21.641 -23.399
    Net Income Before Extra. Items -5.534 -7.921 -16.564 -21.641 -23.399
    Net Income -5.534 -7.921 -16.564 -21.641 -23.399
    Income Available to Common Excl. Extra. Items -5.534 -7.921 -16.564 -21.641 -23.399
    Income Available to Common Incl. Extra. Items -5.534 -7.921 -16.564 -21.641 -23.399
    Diluted Net Income -5.534 -7.921 -16.564 -21.641 -23.399
    Diluted Weighted Average Shares 35.7117 35.6128 32.467 30.1345 29.962
    Diluted EPS Excluding Extraordinary Items -0.15496 -0.22242 -0.51018 -0.71815 -0.78095
    Dividends per Share - Common Stock Primary Issue 0 0 0
    Diluted Normalized EPS -0.15496 -0.19925 -0.51018 -0.71815 -0.78095
    Other, Net 0.249 -0.616 -0.735 0.15 0.04
    Unusual Expense (Income) 0 0.825
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Total Current Assets 111.673 137.862 106.056 72.584 7.537
    Cash and Short Term Investments 106.802 133.82 99.864 71.716 7.343
    Cash 40.27 35.69 4.074 11.259 7.343
    Cash & Equivalents 15.954 16.151 46.155 11.815 0
    Short Term Investments 50.578 81.979 49.635 48.642 0
    Prepaid Expenses 3.376 3.348 5.504 0.766 0.141
    Other Current Assets, Total 1.495 0.694 0.688 0.102 0.053
    Total Assets 133.228 189.466 124.37 72.877 7.718
    Property/Plant/Equipment, Total - Net 1.428 1.101 1.334 0.283 0.122
    Property/Plant/Equipment, Total - Gross 2.387 1.716 1.617 0.378 0.166
    Accumulated Depreciation, Total -0.959 -0.615 -0.283 -0.095 -0.044
    Other Long Term Assets, Total 0.194 0.039 0.217 0.01 0.059
    Total Current Liabilities 14.222 16.996 8.892 1.457 1.763
    Accounts Payable 4.911 3.555 3.075 0.495 0.517
    Accrued Expenses 9.311 13.441 5.817 0.962 1.246
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 14.642 17.204 8.892 1.457 10.82
    Total Long Term Debt 0 0 0 0 7.171
    Long Term Debt 0 7.171
    Other Liabilities, Total 0.42 0.208 0 1.886
    Total Equity 118.586 172.262 115.478 71.42 -3.102
    Redeemable Preferred Stock 0 104.046 17.178
    Common Stock 0.03 0.029 0.027 0.009 0.009
    Additional Paid-In Capital 355.234 318.574 185.196 0.239 0.06
    Retained Earnings (Accumulated Deficit) -236.599 -146.654 -69.805 -32.825 -20.349
    Other Equity, Total -0.079 0.313 0.06 -0.049 0
    Total Liabilities & Shareholders’ Equity 133.228 189.466 124.37 72.877 7.718
    Total Common Shares Outstanding 30.0744 29.5432 26.8694 26.0133 26.0133
    Long Term Investments 19.933 50.464 16.763
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Total Current Assets 96.353 111.673 119.427 135.843 149.885
    Cash and Short Term Investments 91.524 106.802 114.412 129.95 147.035
    Cash 27.403 40.27 8.357 5.744 24.569
    Cash & Equivalents 32.361 15.954 36.6 47.049 38.246
    Short Term Investments 31.76 50.578 69.455 77.157 84.22
    Prepaid Expenses 2.784 3.376 4.52 5.455 2.293
    Other Current Assets, Total 2.045 1.495 0.495 0.438 0.557
    Total Assets 116.13 133.228 147.416 161.39 174.522
    Property/Plant/Equipment, Total - Net 0.573 1.428 1.655 1.886 0.878
    Property/Plant/Equipment, Total - Gross 1.569 2.387 2.53 2.674 1.579
    Accumulated Depreciation, Total -0.996 -0.959 -0.875 -0.788 -0.701
    Long Term Investments 19.175 19.933 26.141 23.516 23.72
    Other Long Term Assets, Total 0.029 0.194 0.193 0.145 0.039
    Total Current Liabilities 9.71 14.222 14.154 18.537 17.867
    Accounts Payable 3.731 4.911 2.88 7.193 2.845
    Accrued Expenses 5.979 9.311 11.274 11.344 15.022
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 9.75 14.642 14.764 19.31 18.038
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0.04 0.42 0.61 0.773 0.171
    Total Equity 106.38 118.586 132.652 142.08 156.484
    Common Stock 0.03 0.03 0.03 0.03 0.029
    Additional Paid-In Capital 365.096 355.234 345.751 333.427 326.006
    Retained Earnings (Accumulated Deficit) -258.24 -236.599 -213.2 -191.494 -169.74
    Other Equity, Total -0.506 -0.079 0.071 0.117 0.189
    Total Liabilities & Shareholders’ Equity 116.13 133.228 147.416 161.39 174.522
    Total Common Shares Outstanding 30.1496 30.0744 29.8673 29.6558 29.5759
    • Annual
    • Quarterly
    2021 2020 2019 2018 2017
    Net income/Starting Line -89.945 -76.849 -36.98 -12.476 -12.235
    Cash From Operating Activities -62.932 -50.818 -33.277 -11.695 -9.827
    Cash From Operating Activities 0.344 0.332 0.188 0.051 0.045
    Non-Cash Items 30.93 15.472 1.611 1.12 1.903
    Cash Interest Paid 0.001 0.001
    Changes in Working Capital -4.261 10.227 1.904 -0.39 0.46
    Cash From Investing Activities 58.952 -52.431 -17.747 -46.754 -0.077
    Capital Expenditures -0.18 -0.052 -0.055 -0.212 -0.077
    Other Investing Cash Flow Items, Total 59.132 -52.379 -17.692 -46.542 0
    Cash From Financing Activities 6.808 118.876 77.366 75.928 7.75
    Issuance (Retirement) of Stock, Net 6.808 118.91 77.925 75.678 0
    Issuance (Retirement) of Debt, Net 0 -0.034 -0.559 0.25 7.75
    Net Change in Cash 2.883 15.627 26.342 17.479 -2.154
    Foreign Exchange Effects 0.055
    Mar 2022 Dec 2021 Sep 2021 Jun 2021 Mar 2021
    Net income/Starting Line -21.641 -89.945 -66.546 -44.84 -23.086
    Cash From Operating Activities -16.091 -62.932 -48.514 -31.172 -13.61
    Cash From Operating Activities 0.038 0.344 0.26 0.173 0.086
    Non-Cash Items 9.375 30.93 22.238 14.371 7.285
    Changes in Working Capital -3.863 -4.261 -4.466 -0.876 2.105
    Cash From Investing Activities 13.413 58.952 38.033 37.267 31.643
    Capital Expenditures -0.005 -0.18 -0.136 -0.136 -0.037
    Other Investing Cash Flow Items, Total 13.418 59.132 38.169 37.403 31.68
    Cash From Financing Activities 0.622 6.808 5.818 1.113 0.441
    Issuance (Retirement) of Stock, Net 0.622 6.808 5.818 1.113 0.441
    Net Change in Cash -2.16 2.883 -4.634 7.208 18.474
    Issuance (Retirement) of Debt, Net 0 0 0
    Foreign Exchange Effects -0.104 0.055 0.029
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Lamond (David A.) Individual Investor 10.1543 3683658 1634720 2022-01-31
    Dominy (Stephen S) Individual Investor 3.9631 1437674 763 2022-01-31
    Lynch (Casey C) Individual Investor 3.2544 1180580 -120000 2022-01-31
    EPIQ Capital Group, LLC Investment Advisor 2.9115 1056191 -1000478 2022-12-31 LOW
    Two Sigma Investments, LP Hedge Fund 2.4701 896084 -61145 2022-12-31 HIGH
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 2.3524 853391 -18615 2022-12-31 LOW
    Pfizer Inc Corporation 1.6539 600000 -1456377 2021-12-31 MED
    Millennium Management LLC Hedge Fund 1.6424 595801 137810 2022-12-31 HIGH
    Low (Philip S) Individual Investor 1.2551 455309 455309 2022-05-19
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.9169 332627 -165208 2022-12-31 LOW
    Thye (Dirk) Individual Investor 0.7744 280911 280911 2022-05-19
    Lowe (Christopher P) Individual Investor 0.7305 265000 175000 2022-03-03 LOW
    Federated Hermes MDTA LLC Investment Advisor/Hedge Fund 0.6904 250458 -264583 2022-12-31 HIGH
    Smith (Karen L) Individual Investor 0.5367 194690 194690 2022-05-19 LOW
    Alphabet, Inc. Venture Capital 0.5213 189122 0 2022-12-31 LOW
    Renaissance Technologies LLC Hedge Fund 0.4248 154100 -180125 2022-12-31 HIGH
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 0.4239 153788 0 2022-12-31 MED
    Holsinger (Leslie) Individual Investor 0.3985 144580 -10920 2022-06-06
    Detke (Michael J) Individual Investor 0.3859 140000 140000 2022-03-03
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.3779 137086 -9128 2022-12-31 LOW

    Why choose Capital.com? Our numbers speak for themselves.

    Capital.com Group

    500K+

    Traders

    92K+

    Active clients monthly

    $53M+

    Monthly investing volume

    $30M+

    Withdrawn each month

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results
    Profit/Loss

    Cortexyme Inc. Company profile

    About Cortexyme Inc

    Cortexyme, Inc. is a clinical stage biopharmaceutical company that is focused on providing disease-modifying therapeutics to treat Alzheimer's and other degenerative diseases. The Company provides 3CLpro inhibitor, COR803 product, is a lead compound for treatment of coronavirus infections. The Company’s products pipeline includes drug candidates for the treatment of central nervous system (CNS) disorders including Alzheimer’s disease; for the treatment of oncology applications including the prevention of oral squamous cell carcinoma, and for the treatment of underserved and chronic conditions such as periodontitis. The Company’s COR388 is for the treatment of Alzheimer’s disease and Parkinson's disease. The Company's COR588 is in Phase I clinical trial and targeting to use in the treatment of periodontal disease and other P. gingivalis-related indications. The Company is also developing COR588, is a second-generation brain penetrant lysine gingipain inhibitor.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Cortexyme Inc revenues was not reported. Net loss increased 17% to $89.9M. Higher net loss reflects Stock-based Compensation in R&D increase from $7M to $15.1M (expense), Stock-based Compensation in GA increase of 99% to $14.8M (expense), General and administrative - Balancing increase of 45% to $14.7M (expense).

    Industry: Biotechnology & Medical Research (NEC)

    269 East Grand Ave
    94080

    Income Statement

    • Annual
    • Quarterly

    News

    A file photo shows a part of a stack of 500 Canadian gold coins, worth $1 million USD according to Sprott Money, is displayed at the precious metals dealer's booth at the Prospectors and Developers Association of Canada (PDAC) annual conference in Toronto

    PRECIOUS-Fed slowdown bets steer gold toward second quarterly rise

    Gold prices slipped on Friday, but the safe-haven metal was bound for its second straight quarterly rise after recent banking turmoil raised hopes of a less-aggressive U.S. Federal Reserve and shored up interest in bullion.

    09:37, 31 March 2023
    People use DBS automated teller machines (ATMs) in Singapore March 31, 2022.

    Singapore's DBS has seen inflows in SVB aftermath, CEO says

    DBS Group, Singapore's largest bank, has benefited from inflows amounting to a "few hundred millions" in the aftermath of the collapse of Silicon Valley Bank, its chief executive said on Friday.

    09:24, 31 March 2023
    Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., March 29, 2023.

    US STOCKS-Futures muted as investors await key inflation data

    U.S. stock index futures were flat on Friday as investors steered clear of big bets ahead of crucial inflation data, amid receding fears of a banking crisis.

    09:16, 31 March 2023
    A file photo of the logo of Australian energy company Origin pictured in Melbourne, Australia, July 3, 2016

    Asia M&As drop to decade low as tumultuous backdrop deters dealmaking

    Mergers and acquisitions (M&A) in the Asia-Pacific region fell to a decade low in the first three months of this year as a tumultuous geopolitical and macroeconomic environment left dealmakers cautious.

    09:14, 31 March 2023
    A file photo of a worker shoveling coal in a supply truck at a yard on the outskirts of Ahmedabad, India, October 25, 2018.

    Coal India surpasses annual output target for first time in 17 years

    Coal India Ltd said on Friday it had breached its annual production target of 700 million tonnes, the first time it had surpassed its goal since the fiscal year that ended in March 2006.

    09:13, 31 March 2023
    A file photo of bull and bear symbols in front of the German stock exchange in Frankfurt, Germany, February 12, 2019.

    Global IPOs marred by banks and recession enjoy few bright spots

    A banking crisis and worries of a recession have dampened the outlook for initial public offerings (IPOs) this year, prompting companies to slow down their plans to go public in what is likely to result in lower fees for investment banks.

    09:06, 31 March 2023
    A file photo of Unicredit Bank logo seen in this illustration taken March 12, 2023.

    UniCredit shareholders gather to vote on CEO's new pay scheme

    Shareholders in UniCredit met on Friday to vote on a new pay scheme for Chief Executive Andrea Orcel designed to reward outperformance with a 30% pay raise.

    09:04, 31 March 2023

    People also watch

    Gold

    1,969.66 Price
    -0.550% 1D Chg, %
    Long position overnight fee -0.0185%
    Short position overnight fee 0.0102%
    Overnight fee time 21:00 (UTC)
    Spread 0.30

    Oil - Crude

    75.76 Price
    +1.830% 1D Chg, %
    Long position overnight fee -0.0156%
    Short position overnight fee -0.0063%
    Overnight fee time 21:00 (UTC)
    Spread 0.03

    Natural Gas

    2.20 Price
    +3.540% 1D Chg, %
    Long position overnight fee -0.4092%
    Short position overnight fee 0.3873%
    Overnight fee time 21:00 (UTC)
    Spread 0.005

    US100

    13,186.80 Price
    +1.680% 1D Chg, %
    Long position overnight fee -0.0249%
    Short position overnight fee 0.0027%
    Overnight fee time 21:00 (UTC)
    Spread 3.0

    Still looking for a broker you can trust?

    Join the 500.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading